Paolo Bossi
University of Brescia
Quality of lifeCancerInternal medicineSurgeryPathologyOncologyIntensive care medicineAdverse effectHead and neck cancerInduction chemotherapyChemotherapyHead and neck squamous-cell carcinomaChemoradiotherapyMucositisDiseaseCetuximabCancer researchRadiation therapyClinical trialMedicine
355Publications
37H-index
4,294Citations
Publications 354
Newest
#1Francesca De Felice (Sapienza University of Rome)H-Index: 20
#2Liliana Belgioia (UniGe: University of Genoa)H-Index: 11
Last. Stefano Arcangeli (University of Milan)H-Index: 25
view all 14 authors...
Abstract Purpose To evaluate efficacy and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy and identify differences in clinical outcomes and severe toxicity rate. Methods PICOS/PRISMA methods were used to identify studies on PubMed, EMBASE and Cochrane Library, 2005–2019. Results Six randomized clinical trials (554 patients) were identified. Weekly cisplatin was not associated with significant overall survival (HR 1.13, 95 % CI 0.84–1.51) and progres...
Source
#1Valentina D. A. Corino (Polytechnic University of Milan)H-Index: 17
#2Marco Bologna (Polytechnic University of Milan)H-Index: 6
Last. Paolo Bossi (University of Brescia)H-Index: 37
view all 20 authors...
Baseline clinical prognostic factors for recurrent and/or metastatic (RM) head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy are lacking. CT-based radiomics may provide additional prognostic information. A total of 85 patients with RM-HNSCC were enrolled for this study. For each tumor, radiomic features were extracted from the segmentation of the largest tumor mass. A pipeline including different feature selection steps was used to train a radiomic signature prognostic for ...
Source
#1Salvatore AlfieriH-Index: 17
Last. Lisa Licitra (University of Milan)H-Index: 68
view all 29 authors...
To identify and validate baseline magnetic resonance imaging (b-MRI) radiomic features (RFs) as predictors of disease outcomes in effectively cured head and neck squamous cell carcinoma (HNSCC) pat...
Source
#1Chiara RomaniH-Index: 19
#2Eliana Bignotti (University of Brescia)H-Index: 23
Last. Paolo BossiH-Index: 37
view all 26 authors...
Olfactory neuroblastoma (ONB) is a rare sinonasal neoplasm with a peculiar behavior, for which limited prognostic factors are available. Herein, we investigate the transcriptional pathways altered in ONB and correlate them with pathological features and clinical outcomes. We analyze 32 ONB patients treated with curative intent at two independent institutions from 2001 to 2019 for whom there is available pathologic and clinical data. We perform gene expression profiling on primary ONB samples and...
Source
#1Daniele Borsetto (Cambridge University Hospitals NHS Foundation Trust)H-Index: 9
#2Mantegh Sethi (Cambridge University Hospitals NHS Foundation Trust)
Last. Paolo Boscolo-Rizzo (UniTS: University of Trieste)H-Index: 25
view all 27 authors...
BACKGROUND Over 50% of patients with head-and-neck squamous cell carcinoma (HNSCC) experience locoregional recurrence, which is associated with poor outcome. In the course of follow-up for patients surviving primary surgery for HNSCC, one might ask: What is the probability of recurrence in one year considering that the cancer has not yet recurred to date? MATERIALS AND METHODS To answer this question, 979 patients surgically treated for HNSCC (i.e. cancer of the oral cavity, oropharynx, hypophar...
Source
#1Cristina Gurizzan (University of Brescia)H-Index: 1
#2Luigi Lorini (University of Brescia)H-Index: 2
Last. Paolo Bossi (University of Brescia)H-Index: 37
view all 18 authors...
Background Oral Potentially Malignant Disorders (OPMD) have a non-negligible malignant transformation rate of up to 8%. Loss of heterozygosity (LOH) in critical chromosomal loci has proven to be the most effective marker in defining the risk of transformation and it is found in about 28% of OPMD and may therefore identify patients carrying higher risk. To date, clinical management of OPMD is limited to surgical excision and clinical surveillance, which however do not fully prevent oral cancer de...
Source
#1Franco IonnaH-Index: 17
#2Paolo BossiH-Index: 37
Last. Francesco PerriH-Index: 34
view all 14 authors...
Squamous cell carcinoma of the head and neck (SCCHN) is a complex group of malignancies, posing several challenges to treating physicians. Most patients are diagnosed with a locally advanced disease and treated with strategies integrating surgery, chemotherapy, and radiotherapy. About 50% of these patients will experience a recurrence of disease. Recurrent/metastatic SCCHN have poor prognosis with a median survival of about 12 months despite treatments. In the last years, the strategy to manage ...
Source
#1Luigi LoriniH-Index: 2
#2Marco MerlanoH-Index: 27
Last. Paolo BossiH-Index: 37
view all 5 authors...
Source
#2Andrea AbateH-Index: 3
Last. Paolo BossiH-Index: 37
view all 14 authors...
Source
#1Francesco Mozzanica (University of Milan)H-Index: 13
#2Letizia Scarponi (University of Milan)H-Index: 3
Last. Antonio Schindler (University of Milan)H-Index: 27
view all 10 authors...
AbstractObjective: Speech impairment is common in patients affected by head and neck cancer and impact on quality of life. Therefore, specific instruments are required for its evaluation. The aim o...
1 CitationsSource